OVERVIEW

KPV (Ac-KPV-NH2) 5 mg is a synthetic tripeptide composed of the amino acids lysine, proline, and valine. It is derived from the C-terminal end of alpha-melanocyte–stimulating hormone (α-MSH), a peptide involved in regulating inflammation and immune responses. The acetylated (Ac-) and amidated (-NH2) modifications enhance its stability and resistance to enzymatic degradation, making it more suitable for laboratory and experimental applications. KPV has been studied for its potential anti-inflammatory properties, particularly in relation to gastrointestinal and skin models. Research suggests it may influence inflammatory signaling pathways, including modulation of cytokine production and nuclear factor-kappa B (NF-κB) activity.

In experimental settings, KPV has attracted interest for its potential role in supporting epithelial barrier integrity and regulating immune responses in the gut. Some preclinical studies have explored its effects in models of inflammatory bowel conditions and localized inflammatory reactions. Unlike broader immunosuppressive agents, KPV is often described in research as having targeted activity with minimal systemic effects, although comprehensive human data remain limited. The 5 mg presentation typically refers to a lyophilized research-grade quantity intended for controlled investigation. As scientific exploration continues, KPV remains categorized primarily as a research peptide, with ongoing studies examining its mechanisms, safety considerations, and broader therapeutic potential.